VistaGen Therapeutics
VTGN
48 hedge funds and large institutions have $2.54M invested in VistaGen Therapeutics in 2026 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 16 closing their positions.
941% more call options, than puts
Call options by funds: $333K | Put options by funds: $32K
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
8.48% less ownership
Funds ownership: 37.18% → 28.7% (-8.5%)
14% less funds holding
Funds holding: 56 → 48 (-8)
36% less capital inflows, than outflows
Capital inflows: $2.84M | Capital outflows: $4.43M
44% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$1.68M |
| 2 |
Renaissance Technologies
New York
|
+$265K |
| 3 |
Two Sigma Investments
New York
|
+$228K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$172K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$124K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$1.75M |
| 2 |
TCG Crossover Management
Palo Alto,
California
|
-$1.53M |
| 3 |
Millennium Management
New York
|
-$260K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$241K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$86K |
VTGN Hedge Fund Activity: Q2 2026 in Review
48 of the 8,355 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2026, worth a combined $2.54M — down 69% from $8.12M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of VTGN and 9 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 15 added.
The largest buyer was Commodore Capital, opening a new position worth an estimated $1.68M. The largest seller was OrbiMed, exiting entirely with an estimated $1.75M sold.
- 48 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2026, down from 56 in Q1 2026.
- Funds reported $2.54M of VistaGen Therapeutics stock for Q2 2026, down 69% quarter-over-quarter.
- 9 funds opened new VistaGen Therapeutics positions in Q2 2026 and 16 closed out, a net change of -7 holders.
- The largest VistaGen Therapeutics buyer in Q2 2026 was Commodore Capital, an estimated $1.68M added.
- The largest VistaGen Therapeutics seller in Q2 2026 was OrbiMed, an estimated $1.75M sold.
Based on aggregated 13F filings for Q2 2026.